Immunogenicity of Leishmania donovani iron superoxide dismutase B1 and peroxidoxin 4 in BALB/c mice: The contribution of Toll-like receptor agonists as adjuvant

Experimental Parasitology

Volumn 129, Issue 3, 2011, Pages 292-298

  Daifalla, Nada S ^a   Bayih, A Genetu ^a   Gedamu, Lashitew ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Leishmania; Peroxidoxin; Superoxide dismutase; Vaccine

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; GLUCOPYRANOSYL LIPID A; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 10; LEISHMANIA VACCINE; RECOMBINANT IRON SUPEROXIDE DISMUTASE B1; RECOMBINANT PEROXIDOXIN 4; RECOMBINANT PROTEIN; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; IMMUNOGENICITY; LEISHMANIA DONOVANI; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TH1 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CYTOKINES; FEMALE; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; LEISHMANIA DONOVANI; LYMPH NODES; MICE; MICE, INBRED BALB C; PEROXIREDOXINS; RECOMBINANT PROTEINS; SPECIFIC PATHOGEN-FREE ORGANISMS; SPLEEN; SUPEROXIDE DISMUTASE; TOLL-LIKE RECEPTORS;

LEISHMANIA DONOVANI; MUS;

EID: 80054727576     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2011.07.001     Document Type: Article

References (47)

1. Ahmed S.B., Touihri L., Chtourou Y., Dellagi K., Bahloul C. DNA based vaccination with a cocktail of plasmids encoding immunodominant Leishmania (Leishmania) major antigens confers full protection in BALB/c mice. Vaccine 2009, 27:99-106.
2. Ajdary S., Alimohammadian M.H., Eslami M.B., Kemp K., Kharazmi A. Comparison of the immune profile of nonhealing cutaneous Leishmaniasis patients with those with active lesions and those who have recovered from infection. Infection and Immunity 2000, 68:1760-1764.
3. Alvar J., Canavate C., Gutierrez-Solar B., Jimenez M., Laguna F., Lopez-Velez R., Molina R., Moreno J. Leishmania and human immunodeficiency virus coinfection: the first 10years. Clinical Microbiology Reviews 1997, 10:298-319.
4. Baldwin S.L., Bertholet S., Kahn M., Zharkikh I., Ireton G.C., Vedvick T.S., Reed S.G., Coler R.N. Intradermal immunization improves protective efficacy of a novel TB vaccine candidate. Vaccine 2009, 27:3063-3071.
5. Baldwin S.L., Shaverdian N., Goto Y., Duthie M.S., Raman V.S., Evers T., Mompoint F., Vedvick T.S., Bertholet S., Coler R.N., Reed S.G. Enhanced humoral and type 1 cellular immune responses with fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 2009, 27:5956-5963.
6. Barr S.D., Gedamu L. Cloning and characterization of three differentially expressed peroxidoxin genes from Leishmania chagasi. Evidence for an enzymatic detoxification of hydroxyl radicals. Journal of Biological Chemistry 2001, 276:34279-34287.
7. Barr S.D., Gedamu L. Role of peroxidoxins in Leishmania chagasi survival. Evidence of an enzymatic defense against nitrosative stress. Journal of Biological Chemistry 2003, 278:10816-10823.
8. Barral A., Barral-Netto M., Yong E.C., Brownell C.E., Twardzik D.R., Reed S.G. Transforming growth factor beta as a virulence mechanism for Leishmania braziliensis. Proceedings of the National Academy of Sciences of the United States of America 1993, 90:3442-3446.
9. Belkaid Y., Hoffmann K.F., Mendez S., Kamhawi S., Udey M.C., Wynn T.A., Sacks D.L. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. Journal of Experimental Medicine 2001, 194:1497-1506.
10. Bertholet S., Goto Y., Carter L., Bhatia A., Howard R.F., Carter D., Coler R.N., Vedvick T.S., Reed S.G. Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine 2009, 27:7036-7045.
11. Campos-Neto A., Webb J.R., Greeson K., Coler R.N., Skeiky Y.A., Reed S.G. Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice. Infection and Immunity 2002, 70:2828-2836.
12. Coler R.N., Goto Y., Bogatzki L., Raman V., Reed S.G. Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells. Infection and Immunity 2007, 75:4648-4654.
13. Croft S.L., Sundar S., Fairlamb A.H. Drug resistance in leishmaniasis. Clinical Microbiology Reviews 2006, 19:111-126.
14. Datta N., Mukherjee S., Das L., Das P.K. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation. European Journal of Immunology 2003, 33:1508-1518.
15. Desjeux P. The increase in risk factors for leishmaniasis worldwide. Transactions of the Royal Society of Tropical Medicine and Hygiene 2001, 95:239-243.
16. Ghalib H.W., Piuvezam M.R., Skeiky Y.A., Siddig M., Hashim F.A., el-Hassan A.M., Russo D.M., Reed S.G. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. Journal of Clinical Investigation 1993, 92:324-329.
17. Gurunathan S., Prussin C., Sacks D.L., Seder R.A. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nature Medicine 1998, 4:1409-1415.
18. Handman E. Leishmaniasis: current status of vaccine development. Clinical Microbiology Reviews 2001, 14:229-243.
19. Harder S., Bente M., Isermann K., Bruchhaus I. Expression of a mitochondrial peroxiredoxin prevents programmed cell death in Leishmania donovani. Eukaryotic Cell 2006, 5:861-870.
20. Heinzel F.P., Sadick M.D., Mutha S.S., Locksley R.M. Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis. Proceedings of the National Academy of Sciences of the United States of America 1991, 88:7011-7015.
21. Iborra S., Parody N., Abanades D.R., Bonay P., Prates D., Novais F.O., Barral-Netto M., Alonso C., Soto M. Vaccination with the Leishmania major ribosomal proteins plus CpG oligodeoxynucleotides induces protection against experimental cutaneous leishmaniasis in mice. Microbes and Infection 2008, 10:1133-1141.
22. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nature Immunology 2004, 5:987-995.
23. Jaafari M.R., Badiee A., Khamesipour A., Samiei A., Soroush D., Kheiri M.T., Barkhordari F., McMaster W.R., Mahboudi F. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome. Vaccine 2007, 25:6107-6117.
24. Kabelitz D. Expression and function of Toll-like receptors in T lymphocytes. Current Opinion in Immunology 2007, 19:39-45.
25. Kaisho T., Akira S. Toll-like receptors as adjuvant receptors. Biochimica et Biophysica Acta 2002, 1589:1-13.
26. Kemp M., Hey A.S., Kurtzhals J.A., Christensen C.B., Gaafar A., Mustafa M.D., Kordofani A.A., Ismail A., Kharazmi A., Theander T.G. Dichotomy of the human T cell response to Leishmania antigens. I. Th1-like response to Leishmania major promastigote antigens in individuals recovered from cutaneous leishmaniasis. Clinical and Experimental Immunology 1994, 96:410-415.
27. Kima P.E., Ruddle N.H., McMahon-Pratt D. Presentation via the class I pathway by Leishmania amazonensis-infected macrophages of an endogenous leishmanial antigen to CD8+ T cells. Journal of Immunology 1997, 159:1828-1834.
28. LoVerde P.T., Carvalho-Queiroz C., Cook R. Vaccination with antioxidant enzymes confers protective immunity against challenge infection with Schistosoma mansoni. Memórias do Instituto Oswaldo Cruz 2004, 99:37-43.
29. Paramchuk W.J., Ismail S.O., Bhatia A., Gedamu L. Cloning, characterization and overexpression of two iron superoxide dismutase cDNAs from Leishmania chagasi: role in pathogenesis. Molecular and Biochemical Parasitology 1997, 90:203-221.
30. Park S.U., Kathaperumal K., McDonough S., Akey B., Huntley J., Bannantine J.P., Chang Y.F. Immunization with a DNA vaccine cocktail induces a Th1 response and protects mice against Mycobacterium avium subsp. paratuberculosis challenge. Vaccine 2008, 26:4329-4337.
31. Piscopo T.V., Mallia A.C. Leishmaniasis. Postgraduate Medical Journal 2006, 82:649-657.
32. Plewes K.A., Barr S.D., Gedamu L. Iron superoxide dismutases targeted to the glycosomes of Leishmania chagasi are important for survival. Infection and Immunity 2003, 71:5910-5920.
33. Raman V.S., O'Donnell J., Bailor H.R., Goto W., Lahiri R., Gillis T.P., Reed S.G., Duthie M.S. Vaccination with the ML0276 antigen reduces local inflammation but not bacterial burden during experimental Mycobacterium leprae infection. Infection and Immunity 2009, 77:5623-5630.
34. Raman V.S., Bhatia A., Picone A., Whittle J., Bailor H.R., O'Donnell J., Pattabhi S., Guderian J.A., Mohamath R., Duthie M.S., Reed S.G. Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis. Journal of Immunology 2010, 185:1701-1710.
35. Reed S.G., Coler R.N., Campos-Neto A. Development of a leishmaniasis vaccine: the importance of MPL. Expert Review of Vaccines 2003, 2:239-252.
36. Reithinger R., Dujardin J.C., Louzir H., Pirmez C., Alexander B., Brooker S. Cutaneous leishmaniasis. The Lancet Infectious Diseases 2007, 7:581-596.
37. Santarem N., Tomas A., Ouaissi A., Tavares J., Ferreira N., Manso A., Campino L., Correia J.M., Cordeiro-da-Silva A. Antibodies against a Leishmania infantum peroxiredoxin as a possible marker for diagnosis of visceral leishmaniasis and for monitoring the efficacy of treatment. Immunology Letters 2005, 101:18-23.
38. Skeiky Y.A., Coler R.N., Brannon M., Stromberg E., Greeson K., Crane R.T., Webb J.R., Campos-Neto A., Reed S.G. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine 2002, 20:3292-3303.
39. Soong C.J., Torian B.E., Abd-Alla M.D., Jackson T.F., Gatharim V., Ravdin J.I. Protection of gerbils from amebic liver abscess by immunization with recombinant Entamoeba histolytica 29-kilodalton antigen. Infection and Immunity 1995, 63:472-477.
40. Stacey K.J., Blackwell J.M. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major. Infection and Immunity 1999, 67:3719-3726.
41. Verthelyi D., Gursel M., Kenney R.T., Lifson J.D., Liu S., Mican J., Klinman D.M. CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection. Journal of Immunology 2003, 170:4717-4723.
42. Webb J.R., Campos-Neto A., Ovendale P.J., Martin T.I., Stromberg E.J., Badaro R., Reed S.G. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infection and Immunity 1998, 66:3279-3289.
43. WHO, 2002. The World Health Report 197-97 [online]. http://www.who.int.htm.
44. WHO, 2004. Scientific Work Group Report on Leishmaniasis. http://www.who.int.
45. Wolday D., Berhe N., Akuffo H., Britton S. Leishmania-HIV interaction: immunopathogenic mechanisms. Parasitology Today 1999, 15:182-187.
46. Yeganeh F., Barkhordari F., Omidi M., Samiei A., Adeli A., Mahboudi F., Kamali-Sarvestani E. Cloning and expression of Leishmania major superoxide dismutase B1: a potential target antigen for serodiagnosis of Leishmaniasis. Iranian Journal of Immunology 2009, 6:130-140.
47. Zimmermann S., Egeter O., Hausmann S., Lipford G.B., Rocken M., Wagner H., Heeg K. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. Journal of Immunology 1998, 160:3627-3630.